Helix BioPharma Corp.

TSX:HBP.TO

Biotechnology

Healthcare
$0.86 -4.70%

-$0.07 today

Market cap
$65.69M
Beta
-0.29
P/E (TTM)
-32.6
EPS (TTM)
-$0.04
52W Low $0.84High $5.40

Volume 0.00M

Average 0.00M

HBP.TO Operating Cash Flow

Cash generated by the company's core business operations during the period.

Helix BioPharma Corp.TSX: HBP.TO

Operating Cash Flow · Q3 FY2026 · quarter ended Apr 2026

Operating cash flow declines year over year

Q3 FY2026 operating cash flow of CA$880K (cash outflow) fell 36.3% year over year, behind the -18.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 93.0% from the prior quarter. Over 3 fiscal years it compounded at -16.2% a year.

Context

  • Operating cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -36.3% toward the trailing-twelve-month pace of -18.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-CA$880K+93.0% QoQ
Last fiscal yearJul 2025
-CA$3.83M-26.6% YoY
LTMApr 2026
-CA$3.21M-18.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.3%——
1 year-26.6%——
3-year CAGR-16.2%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

CAD · from the cash flow

Latest · FY2025
(3.83M) CAD
Year-over-year change
+26.6%

Operating Cash Flow vs competitors

How HBP.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -18.4% is the 3rd highest of 4, against a peer median of -4.2%.
  • Over three fiscal years its annual growth of -16.2% compares with a peer median of -3.1%.
HBP.TO Competitors
Operating Cash Flow for HBP.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$25.77M USD—+60.7%—
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$24.22M CAD-4.2%-4.3%—
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$19.89M USD+84.7%-1.9%35.7%
SVA.TOSernova Corp.LTM Apr 2026CA$5.5M CAD-65.8%-8.9%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$3.21M CAD-18.4%-16.2%—
Peer median (excluding HBP.TO) —-4.2%-3.1%35.7%

Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Net Income(8.04M)(6.56M)(6.29M)(9.26M)(5.21M)
Depreciation & Amortization199K12K13K14K10K
Deferred Income Tax(2.22M)9K000
Stock-Based Compensation664K425K570K3.52M0
Change in Working Capital(54K)(892K)186K485K1.33M
Accounts Receivables(173K)74K217K8K(68K)
Inventory00000
Accounts Payables50K(867K)(106K)00
Other Working Capital69K(99K)75K477K1.4M
Other Non-Cash Items142K500K(5K)31K31K
Operating Cash Flow(9.3M)(6.51M)(5.53M)(5.22M)(3.83M)
Capital Expenditures00(10K)(14K)(2K)
Acquisitions (Net)2.02M05K019K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities2.02K05K00
Investing Cash Flow2.02M0(5K)(14K)17K
Debt Repayment3M0(2.06M)00
Common Stock Issued3.56M2.99M4.15M5.51M2.8M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.56M3.21M999K00
Financing Cash Flow6.56M6.21M3.09M5.51M2.8M
Effect of Forex Changes52K(9K)000
Net Change in Cash(670K)(313K)(2.44M)273K(1.02M)
Free Cash Flow(9.3M)(6.51M)(5.54M)(5.23M)(3.83M)

Helix BioPharma Corp.

TSX:HBP.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.